BCLI Brainstorm Cell Therapeutics Inc

Price (delayed)

$3.85

Market cap

$140.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$136.21M

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of ...

Highlights
BCLI's debt is down by 22% YoY and by 15% from the previous quarter
The EPS has increased by 24% year-on-year but it has declined by 3.1% since the previous quarter
The net income has increased by 18% YoY but it has decreased by 3.3% QoQ
The equity has plunged by 74% YoY and by 46% from the previous quarter
BCLI's quick ratio has shrunk by 63% YoY and by 37% QoQ

Key stats

What are the main financial stats of BCLI
Market
Shares outstanding
36.49M
Market cap
$140.47M
Enterprise value
$136.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.89
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$23.34M
EBITDA
-$23.06M
Free cash flow
-$22.09M
Per share
EPS
-$0.66
Free cash flow per share
-$0.61
Book value per share
$0.22
Revenue per share
$0
TBVPS
$0.52
Balance sheet
Total assets
$18.96M
Total liabilities
$11.11M
Debt
$4.74M
Equity
$7.85M
Working capital
$4.96M
Liquidity
Debt to equity
0.6
Current ratio
1.63
Quick ratio
1.58
Net debt/EBITDA
0.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-88.2%
Return on equity
-143.7%
Return on invested capital
-279.8%
Return on capital employed
-210%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCLI stock price

How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
11.92%
1 week
32.3%
1 month
45.83%
1 year
10.95%
YTD
-3.75%
QTD
39.49%

Financial performance

How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.56M
Net income
-$23.93M
Gross margin
N/A
Net margin
N/A
The net income has increased by 18% YoY but it has decreased by 3.3% QoQ
Brainstorm Cell Therapeutics's operating income has increased by 15% YoY but it has decreased by 6% QoQ

Growth

What is Brainstorm Cell Therapeutics's growth rate over time

Valuation

What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
17.89
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 24% year-on-year but it has declined by 3.1% since the previous quarter
BCLI's price to book (P/B) is 90% more than its last 4 quarters average of 8.4 but 41% less than its 5-year quarterly average of 27.1
The equity has plunged by 74% YoY and by 46% from the previous quarter

Efficiency

How efficient is Brainstorm Cell Therapeutics business performance
The company's return on equity has shrunk by 57% YoY and by 38% QoQ
The return on assets has declined by 32% year-on-year and by 25% since the previous quarter
BCLI's ROIC is up by 20% YoY but it is down by 10% QoQ

Dividends

What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCLI.

Financial health

How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's total assets is 71% more than its total liabilities
Brainstorm Cell Therapeutics's current ratio has shrunk by 63% YoY and by 38% QoQ
BCLI's quick ratio has shrunk by 63% YoY and by 37% QoQ
BCLI's debt is 40% less than its equity
The company's debt to equity has surged by 200% YoY and by 58% QoQ
The equity has plunged by 74% YoY and by 46% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.